Cancer treatment and research communications最新文献

{"title":"Theranostic strategies in prostate cancer: Advances in PSMA PET imaging and radioligand therapy","authors":"Talal Al-Assil,&nbsp;John Han,&nbsp;Nazmul Hasan,&nbsp;Spencer Gibson,&nbsp;John Seneriches,&nbsp;Martin Kim,&nbsp;Jena Yang,&nbsp;Shyam Srinivas,&nbsp;Arash Rezazadeh Kalebasty","doi":"10.1016/j.ctarc.2026.101293","DOIUrl":"10.1016/j.ctarc.2026.101293","url":null,"abstract":"<div><div>Prostate cancer is the most common solid tumor in males, and it remains a leading cause of cancer-related mortality. Clinicians still struggle to detect early metastatic spread and treat patients whose disease no longer responds to conventional therapy, despite advancements in diagnostics and treatment. Theranostic strategies that target prostate-specific membrane antigen (PSMA) have emerged as a promising strategy to resolve these gaps. PSMA-targeted positron emission tomography (PET) provides superior sensitivity and specificity in comparison to conventional modalities, enabling the detection of recurrent or small-volume disease at low prostate-specific antigen (PSA) levels. Simultaneously, PSMA-directed radioligand therapies, including 177Lu-PSMA-617, have demonstrated advances in progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC), with a manageable toxicity profile. This review emphasizes the significance of PSMA-based imaging and treatment, utilizing evidence from landmark trials. It also looks at changing approaches including early in the disease course through use of theranostics and dual-tracer PET imaging. Strategies using the immunomodulatory effects of radioligand therapy and combination treatments including androgen receptor (AR) pathway inhibitors, chemotherapy, or immunotherapy are under research and may improve outcomes. Furthermore, increasing the range of use of theranostics is the development of next-generation radiotracers and techniques to handle PSMA-negative or neuroendocrine variations. Lastly, we address worldwide differences in access to PSMA-targeted devices defined by manufacturing infrastructure, regulatory diversity, and financing that still hinder use. Fully achieving the potential of theranostics in prostate cancer will depend on improvements in patient selection, treatment sequencing, and equitable implementation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101293"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148283117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of glucagon-like peptide 1 receptor and the aggressiveness of extrahepatic cholangiocarcinoma","authors":"Yongyot Varathorn,&nbsp;Mathawee Chanamarnjuntho,&nbsp;Ronnakrit Trakoonsenathong,&nbsp;Charat Kusoltech,&nbsp;Kanyarat Thithuan,&nbsp;Prakasit Sa-ngiamwibool,&nbsp;Charupong Saengboonmee","doi":"10.1016/j.ctarc.2026.101300","DOIUrl":"10.1016/j.ctarc.2026.101300","url":null,"abstract":"<div><div>Previous studies demonstrated that the suppression of GLP-1R expression significantly reduced the aggressiveness of intrahepatic cholangiocarcinoma (iCCA) cells, in vitro and in vivo. However, the clinical significance of GLP-1R in extrahepatic cholangiocarcinoma (eCCA) remains unclear, although this subtype is the most common of bile duct cancer. This study thus aimed to investigate the clinicopathological significance of GLP-1R and to determine its functional roles in eCCA. GLP-1R expression in eCCA tissues was determined using immunohistochemistry. The associations between GLP-1R expression and clinicopathological characteristics and patient survival were examined using univariate analysis and the Kaplan-Meier method with the log-rank test, respectively. Roles of GLP-1R in eCCA cells were investigated using siRNA knockdown, followed by MTT proliferation assays and Transwell migration and invasion assays. Molecular mechanisms were investigated using Western blot analysis. The results showed that high GLP-1R expression was significantly associated with poor histological grading and the mucin production of eCCA (P&lt;0.05). Knockdown of GLP-1R in eCCA cells minimally affected cell proliferation, but significantly suppressed cell migration and invasion (P&lt;0.05). Suppressing GLP-1R expression inhibited epithelial-mesenchymal transition (EMT) in CCA cells and reduced the expression of matrix metalloproteinases 2 and 9. The common upstream regulators of EMT, namely STAT3 and Akt signaling pathways, were also suppressed after GLP-1R silencing. In conclusion, similar to iCCA, high GLP-1R expression is associated with aggressive phenotypes of eCCA. Inhibition of GLP-1R expression might then be another strategy to suppress the progression of CCA in both subtypes.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101300"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of national cancer care network guideline-adherent treatment differences as a contributor to racial disparities in epithelial and non-epithelial ovarian cancer survival","authors":"Marilyn Barragan,&nbsp;Shannon MacLaughlan David,&nbsp;Zhengia Chen,&nbsp;Kimberly Richardson,&nbsp;Wenan Qiang,&nbsp;Denana Miodragovic,&nbsp;Caryn E. Peterson","doi":"10.1016/j.ctarc.2026.101307","DOIUrl":"10.1016/j.ctarc.2026.101307","url":null,"abstract":"<div><h3>Objective</h3><div>To assess National Comprehensive Cancer Network (NCCN) guideline concordance and survival for epithelial and nonepithelial ovarian cancer in Black and White patients. Guideline-concordant care is defined as treatment consistent with NCCN recommendations based on tumor subtype and stage at diagnosis.</div></div><div><h3>Methods</h3><div>This retrospective study included epithelial and nonepithelial ovarian cancer cases from the National Cancer Database from 2005 to 2015 for patients of White or Black race. Outcomes were NCCN guideline concordance and five-year survival following diagnosis. Factors significantly associated with guideline concordance and five-year survival in bivariate analyses were included in multivariable survival models. Survival was assessed using Kaplan–Meier estimates with log-rank tests, and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models.</div></div><div><h3>Results</h3><div>Concordance with evidence-based treatment guidelines was lower among Black patients with epithelial histotypes, with no racial difference for nonepithelial types. Black patients also had a higher burden of nonepithelial histotypes relative to White patients. After adjustment for clinical and sociodemographic factors, Black patients had a higher risk of death than White patients (HR = 1.15, 95% CI 1.11–1.18), which was attenuated slightly after inclusion of guideline-concordant treatment in the model (HR = 1.13, 95% CI 1.09–1.17).</div></div><div><h3>Conclusions</h3><div>Guideline-concordant care was associated with racial differences in survival, but the modest association suggests that additional unmeasured factors likely influence outcomes. Limitations include exclusion of cases missing stage, inability to evaluate factors occurring earlier in the treatment trajectory, and absent data regarding the extent of surgical cytoreduction.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101307"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond hyponatremia: serum sodium below 137 mEq/L and postoperative sodium trajectory as prognostic markers in resected non-small cell lung cancer","authors":"Seyda Ors Kaya,&nbsp;Kenan Can Ceylan,&nbsp;Serap Yıldız,&nbsp;Yunus Emre Bal,&nbsp;Yunus Emre Pek,&nbsp;Fehri İlhan,&nbsp;Mustafa Şahin","doi":"10.1016/j.ctarc.2026.101314","DOIUrl":"10.1016/j.ctarc.2026.101314","url":null,"abstract":"<div><h3>Background</h3><div>Clinical hyponatremia (serum sodium &lt;135 mEq/L) is an established adverse prognostic factor in advanced malignancies, but the prognostic significance of serum sodium within the normal range remains unclear in resected non-small cell lung cancer (NSLC). We evaluated whether preoperative serum sodium below 137 mEq/L predicts survival after curative resection.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included 255 patients undergoing curative resection for NSCLC (165 pN0, 90 pN2). Overall survival was the primary endpoint. Preoperative serum sodium was analyzed using Kaplan–Meier analysis and multivariable Cox regression adjusted for age, sex, histology, tumor size, platelet count, and nodal status. One-year postoperative sodium was available in 210 patients for exploratory trajectory analysis.</div></div><div><h3>Results</h3><div>Preoperative sodium &lt;137 mEq/L was present in 56 patients (22.0%) and was associated with shorter median survival than sodium ≥137 mEq/L (32.7 vs. 68.4 months; <em>p</em> = 0.007). After adjustment, sodium &lt;137 mEq/L remained an independent predictor of poor survival (HR=2.02, 95% CI 1.34–3.04; <em>p</em> &lt; 0.001). Patients with sodium 135–136 mEq/L had survival comparable to clinical hyponatremia (&lt;135 mEq/L; <em>p</em> = 0.587) but significantly worse than sodium ≥137 mEq/L (<em>p</em> = 0.001). Exploratory trajectory analysis showed progressively worse survival from the Normal→Normal to the Low→StillLow group (<em>p</em> &lt; 0.001). Postoperative sodium &lt;137 mEq/L was also associated with worse survival in stage I disease (<em>p</em> = 0.017).</div></div><div><h3>Conclusions</h3><div>Preoperative serum sodium below 137 mEq/L is an independent prognostic marker in resected NSCLC. Exploratory postoperative sodium trajectory may provide additional prognostic information and warrants prospective external validation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101314"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma","authors":"Yixuan Lee,&nbsp;Nicole-Ann Lim,&nbsp;Rowena Lee Ying Kwan,&nbsp;Jason Yongsheng Chan","doi":"10.1016/j.ctarc.2026.101312","DOIUrl":"10.1016/j.ctarc.2026.101312","url":null,"abstract":"<div><div>Tumor-agnostic therapies focus on shared molecular biomarkers independent of tissue of origin, allowing a single drug to target a common biomarker across different tumor types. Such targets with regulatory drug approvals include <em>NTRK</em> fusion, <em>RET</em> fusion, BRAF V600E mutation, <em>FGFR1</em> rearrangement, HER2 overexpression, microsatellite instability or mismatch repair deficiency (MSI-H/dMMR), and high tumor mutational burden (TMB-H). Novel strategies against molecular alterations such as <em>NRG1</em> fusion, <em>ALK</em> fusion, <em>MTAP</em> loss, KRAS G12C, TP53 Y220C and homologous repair deficiency (HRD) have also emerged. While the list of potential tumor-agnostic biomarkers continues to expand, contemporary efforts are still predominantly focused on solid cancers over hematological malignancies, including lymphoma, representing a peculiar and perhaps unwarranted strategic gap. In this review, we thus provide a narrative overview of currently approved tumor-agnostic therapies and highlight emerging biomarkers, addressing the need to focus on their potential application beyond solid tumors.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101312"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitor Outcomes Across Child-Pugh A, B, and C Hepatocellular Carcinoma: A Real-World Integrated Health-System Cohort","authors":"Alireza Tojjari,&nbsp;Yuming Shi,&nbsp;Stela Celaj,&nbsp;Andy Y. Wu,&nbsp;John Rhee,&nbsp;David A. Geller,&nbsp;Scott W. Biggins,&nbsp;Anwaar Saeed","doi":"10.1016/j.ctarc.2026.101320","DOIUrl":"10.1016/j.ctarc.2026.101320","url":null,"abstract":"<div><h3>Background</h3><div>Pivotal first-line immune checkpoint inhibitor (ICI) trials in advanced hepatocellular carcinoma (HCC) largely restricted enrollment to patients with Child-Pugh A liver function, leaving outcomes in patients with more advanced hepatic dysfunction poorly defined. We evaluated survival, tumor response, and early mortality across Child-Pugh A, B, and C classes in a real-world integrated health-system cohort.</div></div><div><h3>Methods</h3><div>We identified 264 consecutive patients with HCC who received first-line ICI-based systemic therapy at the University of Pittsburgh Medical Center between September 2015 and November 2024, with follow-up through December 2025. Child-Pugh class was re-adjudicated at ICI initiation. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, objective response rate, disease control rate, and 90-day mortality.</div></div><div><h3>Results</h3><div>The cohort included 113 patients with Child-Pugh A, 124 with Child-Pugh B, and 27 with Child-Pugh C liver function. Median overall survival was 25.0 months, 13.3 months, and 4.2 months, respectively. Ninety-day mortality was 5.4%, 16.3%, and 40.7%, while objective response rate was 25.5%, 17.0%, and 5.6%. In multivariable Cox regression, Child-Pugh B and C remained independently associated with mortality compared with Child-Pugh A. Among patients who survived at least 90 days, disease control in Child-Pugh C was 38.5%, approaching that observed in Child-Pugh A.</div></div><div><h3>Conclusions</h3><div>In this real-world HCC cohort, worsening Child-Pugh class was associated with progressively shorter survival and higher early mortality after first-line ICI therapy. Although outcomes in Child-Pugh C were poor overall, a subset of patients experienced durable survival or disease control. These findings support careful individualized treatment consideration rather than automatic exclusion of selected Child-Pugh C patients from ICI-based therapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101320"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized controlled trial of home-based combined exercise training for improving inflammatory markers and physical function in breast cancer survivors","authors":"Parisa Jamali,&nbsp;Rostam Alizadeh,&nbsp;Ehsan Amiri,&nbsp;Najmeh Rezaeinezhad","doi":"10.1016/j.ctarc.2026.101427","DOIUrl":"10.1016/j.ctarc.2026.101427","url":null,"abstract":"<div><h3>Objective</h3><div>The recurrence of breast cancer is a significant concern for survivors of the disease. This study aimed to examine the impact of 16 weeks of home-based combined exercise training (HET) and aerobic exercise training (AE) on biological markers related to breast cancer and physical function in breast cancer survivors.</div></div><div><h3>Methods</h3><div>Forty-two breast cancer survivors were randomly assigned to three groups: control, HET, and AE. HET comprised a combination of resistance and aerobic exercise training conducted at home. The interventions were performed three times per week for 16 weeks. Blood samples and physical performance were evaluated before and after the intervention period.</div></div><div><h3>Results</h3><div>The findings indicated that both AE and HET diminished the inflammatory markers interleukin 1β (IL-1β), interferon-gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and insulin-like growth factor 1 (IGF-1), as well as body weight, body fat percentage, and body mass index, compared with the control group. Furthermore, both exercise interventions significantly increased IL-10 and sex hormone-binding globulin (SHBG) and improved cardiorespiratory fitness and flexibility compared with the control group. In addition, compared with the AE group, HET training produced significantly greater improvements in IL-10, SHBG, and upper- and lower-limb strength, and a greater reduction in body fat percentage.</div></div><div><h3>Conclusion</h3><div>These findings suggest that both AE and HET can improve cancer-related biomarkers in breast cancer survivors; however, HET appears to provide superior benefits for these biomarkers and physical performance compared with AE.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"49 ","pages":"Article 101427"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical relative biological effectiveness of carbon-ion versus photon radiotherapy derived from tumor control probability models in locally advanced non-small cell lung cancer","authors":"Yong-Long Liu,&nbsp;Ning-Yi Ma,&nbsp;Ya-Qi Li,&nbsp;Xing-Wen Fan,&nbsp;Jian Chen,&nbsp;Jing Mi,&nbsp;Zi-Zhou Mao,&nbsp;Meng-Yao Lu,&nbsp;Jun-Chao Chen,&nbsp;Ying Guo,&nbsp;Xiao-Li Liu,&nbsp;Jing-Fang Mao,&nbsp;Guo-Liang Jiang,&nbsp;Kai-Liang Wu","doi":"10.1016/j.ctarc.2026.101357","DOIUrl":"10.1016/j.ctarc.2026.101357","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to estimate the clinical relative biological effectiveness (cRBE) of carbon-ion radiotherapy (CIRT) versus photon radiotherapy (PRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving combined radiotherapy and systemic therapy. cRBE was calculated using the equivalent uniform dose (EUD) corresponding to 50% tumor control (D₅₀), derived from tumor control probability (TCP) modeling with 3-year locoregional control (LRC) as the primary endpoint.</div></div><div><h3>Methods</h3><div>Patients treated between 2016 and 2023 were identified. Propensity score matching was applied to balance CIRT and PRT cohorts. LRC was estimated by the Kaplan-Meier method and Cox regression. Gross tumour volume dose-volume histograms were converted to biologically effective dose (BED) and EUD. Logistic TCP models were fitted by maximum likelihood estimation. cRBE was estimated as the ratio of the D₅₀ physical doses for PRT and CIRT.</div></div><div><h3>Results</h3><div>A total of 244 patients were included. The CIRT group demonstrated significantly improved LRC compared with the PRT group (<em>p</em> = 0.033). The best-fitted TCP parameters for 3-year LRC were D₅₀ = 15.44 Gy, k = 2.52, n = 1.00 for CIRT, and D₅₀ = 59.94 Gy, k = 4.65, n = 1.00 for PRT. The estimated cRBE for locoregional control was 3.88.</div></div><div><h3>Conclusion</h3><div>CIRT was associated with improved locoregional tumor control compared with PRT in patients with LA-NSCLC. In addition, to our knowledge, this study is the first to provide a preliminary, model-dependent estimate of the clinical RBE for tumor control in LA-NSCLC using TCP modeling with 3-year LRC as the endpoint.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101357"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148696981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of FUBP1 in Colorectal cancer and association with immune microenvironment characteristics","authors":"Zhenxiang Li,&nbsp;Yanfang Zhao,&nbsp;Yanli Si,&nbsp;Qi Su,&nbsp;Xin Meng,&nbsp;Liping Guan","doi":"10.1016/j.ctarc.2026.101343","DOIUrl":"10.1016/j.ctarc.2026.101343","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate FUBP1 expression, its prognostic value, impact on the tumor microenvironment (TME), and drug sensitivity in colorectal cancer (CRC), and to explore its potential underlying mechanisms.</div></div><div><h3>Methods</h3><div>Using data from The Cancer Genome Atlas (TCGA), we analyzed FUBP1 expression in CRC, evaluated its prognostic value via survival analysis and nomogram construction, performed pathway enrichment analysis, and assessed immune cell infiltration and Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) scores. We further conducted immunohistochemistry (IHC) validation on an independent institutional cohort and analyzed the Gene Expression Omnibus (GEO) single-cell RNA sequencing dataset GSE132465 (<em>n</em> = 63,689 cells) to examine the association between FUBP1 expression and the tumor immune microenvironment at single-cell resolution.</div></div><div><h3>Results</h3><div>FUBP1 was highly expressed in CRC (<em>P</em> &lt; 0.001), particularly in younger patients. High FUBP1 expression was associated with improved overall survival in univariate analysis (HR = 0.68, <em>P</em> = 0.028), yet this association was not maintained as an independent prognostic factor after adjustment for other clinical covariates (HR = 0.722, <em>P</em> = 0.098). Immunohistochemistry results from the independent cohort confirmed upregulated FUBP1 protein in 90% of CRC specimens. Single-cell analysis revealed that FUBP1-high cell clusters exhibited markedly reduced immune cell infiltration (35.97%vs 62.96%, <em>P</em> &lt; 0.001), indicating an immunosuppressive \"cold\" tumor microenvironment. Tumors with high FUBP1 expression also displayed elevated PD-L1, PD-1, and CTLA4 expression, lower half-maximal inhibitory concentration (IC50) values for oxaliplatin, irinotecan, and 5-fluorouracil, and higher Immune Phenotype Score (IPS) for anti-PD-1 monotherapy or combined anti-CTLA-4 immunotherapy. FUBP1 expression was correlated with increased expression of MYC, TP53, and their downstream target genes (CCND1, CDK4, BAX, CDKN1A).</div></div><div><h3>Conclusion</h3><div>FUBP1 is highly expressed in CRC and associated with an immunosuppressive \"cold\" tumor microenvironment characterized by decreased immune cell infiltration, while it correlates with favorable chemotherapeutic sensitivity. FUBP1 may serve as a potential predictive biomarker for responses to chemotherapy and immunotherapy, rather than an independent prognostic indicator for survival. Its linkage to MYC and TP53 signaling pathways warrants further mechanistic investigation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"49 ","pages":"Article 101343"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agrimol B induces apoptosis and ferroptosis in acute monocytic leukemia by targeting EGFR/ERK1/2 signaling and activating SIRT1","authors":"Ting Ma,&nbsp;Qi Wang,&nbsp;Hao Wang,&nbsp;Ke Li,&nbsp;Dan Zhao,&nbsp;Wenjie Huang,&nbsp;Tao Li,&nbsp;Dantong Lyu,&nbsp;Hong Hong,&nbsp;Yue Liu,&nbsp;Min Wang,&nbsp;Jiuqing Gao,&nbsp;Xin Meng,&nbsp;Haiyan Zhang,&nbsp;Xu Wang,&nbsp;Bin Wu","doi":"10.1016/j.ctarc.2026.101441","DOIUrl":"10.1016/j.ctarc.2026.101441","url":null,"abstract":"<div><div>Leukemia is an aggressive hematologic malignancy with high global morbidity and mortality. Despite advances in CAR-T cell therapy and targeted treatments, acute myeloid leukemia and high-risk relapsed cases continue to face formidable therapeutic challenges owing to heterogeneity and drug resistance. Agrimol B (AB), a bioactive natural compound isolated from the edible and medicinal plant <em>Agrimonia pilosa Ledeb</em>., has demonstrated notable anticancer potential. However, its role in leukemia has not yet been investigated. Here, we demonstrate that AB significantly reduces leukemia burden in an Acute Monocytic Leukemia (AMoL) mouse model and suppresses proliferation, invasion, and migration of THP-1 cells in vitro. Mechanistically, AB interacts with EGFR and inhibits ERK1/2 signaling, thereby activating FOXO1. In addition, AB upregulates SIRT1 expression and promotes FOXO1 deacetylation, leading to HMOX1 activation and subsequently triggers ferroptosis. These findings indicate that Agrimol B exerts potent anti-leukemic activity through multiple mechanisms, highlighting its potential as a therapeutic candidate for AMoL.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"49 ","pages":"Article 101441"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}